Emergent BioSolutions Inc. [NYSE: EBS] stock went on a downward path that fall over -34.87% on Wednesday, amounting to a one-week price decrease of less than -36.01%. The company report on November 8, 2022 that Emergent BioSolutions Reports Financial Results For Third Quarter 2022.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
“For more than 20 years, Emergent has been a dependable partner to customers, including the U.S. and allied governments, in helping prepare for public health threats through our products, services, and development programs,” said Robert G. Kramer, president and CEO. “As we continue to strengthen our operations, be guided by financial discipline, and evaluate opportunities for growth, we remain confident in our ability to deliver results for our patients, customers, and shareholders.”.
Over the last 12 months, EBS stock dropped by -63.38%. The one-year Emergent BioSolutions Inc. stock forecast points to a potential upside of 68.6. The average equity rating for EBS stock is currently 2.40, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $638.90 million, with 50.00 million shares outstanding and 44.79 million shares in the current float. Compared to the average trading volume of 629.68K shares, EBS stock reached a trading volume of 3884024 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Emergent BioSolutions Inc. [EBS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EBS shares is $40.93 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EBS stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Emergent BioSolutions Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 29, 2022. The new note on the price target was released on January 20, 2022, representing the official price target for Emergent BioSolutions Inc. stock.
The Average True Range (ATR) for Emergent BioSolutions Inc. is set at 1.45, with the Price to Sales ratio for EBS stock in the period of the last 12 months amounting to 0.40. The Price to Book ratio for the last quarter was 0.42, with the Price to Cash per share for the same quarter was set at 7.20. Price to Free Cash Flow for EBS in the course of the last twelve months was 5.05 with Quick ratio for the last quarter at 2.40.
EBS Stock Performance Analysis:
Emergent BioSolutions Inc. [EBS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -36.01. With this latest performance, EBS shares dropped by -35.33% in over the last four-week period, additionally sinking by -54.06% over the last 6 months – not to mention a drop of -63.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EBS stock in for the last two-week period is set at 23.08, with the RSI for the last a single of trading hit 17.79, and the three-weeks RSI is set at 26.68 for Emergent BioSolutions Inc. [EBS]. The present Moving Average for the last 50 days of trading for this stock 20.89, while it was recorded at 18.47 for the last single week of trading, and 32.08 for the last 200 days.
Insight into Emergent BioSolutions Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Emergent BioSolutions Inc. [EBS] shares currently have an operating margin of +22.21 and a Gross Margin at +54.64. Emergent BioSolutions Inc.’s Net Margin is presently recorded at +12.88.
Return on Equity for this stock inclined to 15.06, with Return on Assets sitting at 7.90.
Emergent BioSolutions Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 3.90.
Emergent BioSolutions Inc. [EBS] Insider Position Details
There are presently around $524 million, or 85.70% of EBS stock, in the hands of institutional investors. The top three institutional holders of EBS stocks are: BLACKROCK INC. with ownership of 8,532,837, which is approximately -2.28% of the company’s market cap and around 0.50% of the total institutional ownership; VANGUARD GROUP INC, holding 5,090,427 shares of the stock with an approximate value of $65.41 million in EBS stocks shares; and STATE STREET CORP, currently with $53.34 million in EBS stock with ownership of nearly 19.633% of the company’s market capitalization.
Positions in Emergent BioSolutions Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 87 institutional holders increased their position in Emergent BioSolutions Inc. [NYSE:EBS] by around 4,765,024 shares. Additionally, 140 investors decreased positions by around 5,100,847 shares, while 35 investors held positions by with 30,916,691 shares. The mentioned changes placed institutional holdings at 40,782,562 shares, according to the latest SEC report filing. EBS stock had 20 new institutional investments in for a total of 966,078 shares, while 44 institutional investors sold positions of 896,450 shares during the same period.